Chronic pressure ulcers (PrUs), ulcers that fail to progress through the expected phases of wound healing in a timely fashion, are not only a concern for the patients afflicted with them, but are also a significant burden for the long-term-care facilities in which patients reside. The heel is the second most common location for PrUs. Morbidity and mortality rates for heel PrUs, particularly in the diabetic population, are alarming. Therefore, a consistently effective, cost-conscious, and user-friendly topical treatment for heel ulcers would be welcomed by patients and clinicians. This article describes a marked and rapid improvement in wound granulation in 3 older adult patients following weekly treatment for 8 weeks of chronic (Q1-year duration) heel ulcers with an easy-to-use, cost-effective, topical, formulated collagen gel.
INTRODUCTION
Although multiple risk factors play a part in the occurrence of pressure ulcers (PrUs), unrelieved or improperly relieved pressure on tissue, particularly over bony prominences, has long been known to be a factor in tissue ischemia and PrU development. 1, 2 The cost of treating PrUs is high. A 2009 report sets PrU treatment costs at $11 billion per year. 3 Factoring in PrU-associated complications, individual treatment costs can exceed $120,000. 4, 5 The heel is the second most common location for PrUs, with reports of prevalence ranging from 18% to 29% of all PrUs. 6, 7 Heels are also the most common site of deep tissue injury PrUs, 8 accounting for 41% of reported deep tissue injuries. 9 Diabetes mellitus (DM) is a well-documented risk factor for development of foot ulcers because of a combination of neuropathy, ischemia, and/or structural problems of the foot. 10 Although less frequent than forefoot ulcers in persons with diabetes, heel ulcers are more costly to treat, are less likely to heal, and are associated with higher rates of limb loss and functional disability. 11, 12 Therefore, new, effective topical treatments for heel PrUs are needed by clinicians in order to successfully pursue ulcer healing and limb salvage. The purpose of this case study was to evaluate the ability of type I formulated collagen gel (Excellagen; Cardium Therapeutics/Tissue Repair Company, San Diego, California) to promote healing of chronic heel PrUs in 3 older adult patients with diabetes.
TECHNIQUES
The 3 patients discussed in this clinical concept study reside at a long-term-care facility (LTCF) in Pennsylvania. Study inclusion criteria were (1) presence of a chronic (present for Q1 year) heel PrU; (2) no active osteomyelitis or infection; and (3) no malignancy in the ulcer. Internal review board approval was not necessary to conduct these trials on this patient population per the facility's administrator. However, individual patient consent was required by the research team. Potential patients were screened for their ability to meet the inclusion criteria. Upon identification of appropriate patients, each patient (or their legally authorized representative) was required to provide written consent to participate in the study. Written consent was obtained after a comprehensive explanation of the trial product, treatment procedures, and protocols for obtaining case study information.
The determination of each patient's ability to understand and give consent to participate in the trial was made by reviewing the patient's Minimum Data Set version 3.0 cognitive section and review of the patient's mental capability as established by their physicians. The initial screening included a total of 5 patients; however, 2 dropped out prior to any application of the trial product because of impending discharge. Those patients reported they did not want to participate from the home setting.
Three patients enrolled in and completed the trial. Patients 1 and 2 are capable of making their own healthcare decisions and signed the consent form themselves. Because of patient 3's impaired cognitive status (Alzheimer dementia), product and trial information were provided to his son, the legally authorized representative. Written consent to participate in the trial was obtained from the son.
In addition to weekly treatment with the formulated collagen gel, facility wound management personnel were instructed to maintain each patient's individual plan of care per the established facility protocols: pressure-reducing support surfaces, pressure-reducing heel devices, repositioning at least every 2 hours, nutritional interventions, and medication and laboratory monitoring.
The author assessed each ulcer weekly, documenting detailed wound descriptions to include measurements, tissue type, drainage, odor, and condition of peripheral ulcer skin. The treatment procedure for each patient was uniform. Each patient was premedicated with analgesics or mild narcotics as ordered by his/her physician prior to performance of sharp debridement. Sharp debridement was performed as clinically indicated based on the presence of nonviable tissue in the ulcer bed. Saline-based cleanser was utilized to clean the ulcers after debridement and prior to the application of formulated collagen gel. Each patient was treated with 1.0 mL of type I formulated collagen gel weekly. A nonadherent, hypoallergenic secondary dressing with bordered adhesive was applied to each patient. The Wong-Baker FACES Pain Scale (FPS) 13 was utilized to assess patient comfort throughout the duration of the trials. This is a self-assessment method in which patients select from a series of 6 face images (each also numerically identified) to rate their pain intensity.
CASE DESCRIPTIONS Patient 1: 81-Year-Old Woman
This patient had a right heel PrU for 12 months that was present on admission to the facility (Figure 1 ). The etiology of the PrU was reportedly due to ill-fitting shoes causing repetitive pressure over an extended period. Documentation review revealed that the ulcer had not achieved more than 10% granulation tissue despite various topical interventions including autolytic debridement and moist wound dressings. Swab cultures had been performed 3 times in the past 12 months, each of which was negative for bacterial infection. Pressure-reducing devices, which have been utilized since the ulcer developed, included dual-therapy low air loss/alternating pressure support surface and foam heel boots. Comorbid conditions consist of DM and peripheral vascular disease (PVD). With assistance, the patient is mobile for repositioning in bed, transfer with a wheeled walker, and walk short distances (e20 feet). Nutritional intakes vary with meal consumption, with a weekly meal average ranging from 60% to 90% intake. Glucose monitoring is performed twice daily, via finger sticks, with insulin being administered per physician's orders.
Patient 2: 75-Year-Old Man
This patient has had a left heel PrU for the past 15 months; this PrU was the reason for the patient's admission to the LTCF (Figure 2 ). The etiology of the PrU was reportedly due to a combination of ill-fitting boots and wearing of those boots nearly 24 hours per day. Off-loading devices, in use since the time of the patient's admission to the LTCF, include alternating air mattress and foam heel devices to off-load pressure. The ulcer has been stagnant in size and tissue type, despite various topical treatments, including ionic zinc ointment and cadexomer iodine. Nonviable tissue was debrided both via sharp method and via autolysis over this time frame; however, granulation tissue failed to grow. Swab culture prior to initiation of this trial was negative for bacterial infection. The patient is mobile with assistance to transfer (due to nonYweight bearing on the left lower extremity secondary to the ulcer) and is then independent in his wheelchair for mobility within the LTCF. He is independent for personal hygiene, eating, and grooming. He does require minimal assistance for safety, to get in and out of the shower. Nutritional status is stable; he consumes 100% of all meals. Comorbid factors consist of DM, PVD, and congestive heart failure. He receives insulin injections as ordered and daily fasting glucose via finger stick.
Patient 3: 79-Year-Old Man
This patient, residing in a LTCF for 3 years, developed a PrU on his right outer heel 13 months ago (Figure 3 ). The ulcer developed secondary to pressure from the foot rests on his wheelchair. Despite multiple topical treatments, including carboxymethylcellulose with 1.2% ionic silver and Leptospermum scoparium, none were able to achieve 100% granulation tissue in the wound bed. Pressure-reducing devices of alternating air mattress to bed and cushion to wheelchair have been utilized since admission to the LTCF. Various types of pressure-reducing devices were attempted to prevent and decrease pressure on his heels; however, he continuously removed all devices. Currently, soft cushioned ''heel boots'' are utilized as best as possible. He continues to remove them frequently, and staff replaces the boots multiple times per shift. Explanation and reminders of why he needed the devices were unsuccessful because of impaired memory and cognition related to Alzheimer dementia. Further chart review disclosed that the ulcer tissue fluctuated between 75% and 100% slough tissue since the ulcer had developed. Swab culture, obtained prior to initiation of treatment with type I formulated collagen gel, was negative for bacterial infection of the wound. The patient is fully dependent on staff for transfers and mobility in wheelchair. He is able to move his legs, but the movement is not purposeful enough for ambulation. Although the patient is able to feed himself, he requires staff assistance to finish his meals as he tires easily and stops eating unless cues and assistance are given. The patient requires total care for all other activities of daily living. With staff assistance, meal intakes are 95% to 100%. In addition to Alzheimer dementia, he has DM, PVD, and hypertension. He receives oral medication for diabetes and has routine laboratory work to monitor his fasting glucose.
RESULTS

Patient 1
Just prior to the first application of type I formulated collagen gel, the ulcer measured 2.6 Â 2.0 Â 0.8 cm (postdebridement), and the periwound tissue was reddened with erythema ( Figure 1A ). Prior to sharp debridement, the wound bed consisted of 95% nonviable tissue. Pressure off-loading was achieved with a foam heel device as prescribed by the patient's physician. The follow-up visit on week 1 revealed a 35% reduction in wound volume (2.5 Â 1.8 Â 0.6 cm), as well as decreased erythema in the periwound tissue ( Figure 1B) . At the week 2 visit, the ulcer displayed further improvement, measuring 2.3 Â 1.6 Â 0.6 cm ( Figure 1C ). By week 4 (after 4 applications of type I collagen gel), the ulcer measured 1.8 Â 0.9 Â 0.4 cm, representing an 84% reduction in volume ( Figure 1D) . At week 7, the wound had decreased in volume by 99% (1.5 Â 0.2 Â 0.1 cm; Figure 1E ). At the final visit (week 8), the ulcer displayed granulation tissue over 100% of the wound bed and an overall reduction in area of 98% (0.9 Â 0.1 Â 0.0 cm; Figure 1F ). Topical protective ointment was initiated at week 8. In the 4 weeks following the study period, this ulcer progressed to complete closure. Although this patient remains at risk of skin breakdown, the ability to fully granulate and dramatically reduce the area of this ulcer within the 8-week study period and to ultimately progress to wound closure has improved her quality of life and overall prognosis.
Patient 2
At the start of care, the ulcer measured 5.5 Â 3.1 Â 0.4 cm with calloused periwound edges (Figure 2A) . Wound drainage consisted of minimal amount of serosanguineous exudate without foul odor. After administration of premedication and allowing for the appropriate time for medication to take effect, the wound bed tissue was sharply debrided to remove all nonviable tissue followed by application of the formulated collagen gel. Sharp debridement (as needed) and treatment with type I formulated Figure 2B ). Minimal sharp debridement was necessary at this visit. The ulcer continued to display increased granulation tissue and decreased size throughout the consecutive weekly visits. At week 2, the wound had decreased in volume by 52% (4.5 Â 2.4 Â 0.3 cm; Figure 2C ). At the halfway point of the study (week 4), the ulcer had decreased volumetrically by 67% (3.6 Â 2.1 Â 0.3 cm; Figure 2D ). Sharp debridement was no longer required after the week 5 visit. On the final visit (week 8), the wound was 100% granulated and measured 1.7 Â 1.1 Â 0.1 cm, an ultimate volumetric reduction of 97%, and a surface area reduction of 89% ( Figure 2G ). Topical treatment was changed to protective ointment at week 8. In the 4 weeks following the study period, this ulcer continued to improve with decreasing wound volume and maintenance of 100% granulation tissue. Although the patient remains at risk of future skin breakdown, his prognosis has improved with the improvement of this particular ulcer.
Patient 3
At the start of study treatment, the ulcer measured 2.3 Â 2.2 Â 1.4 cm with 90% nonviable tissue in the wound bed ( Figure 3A ).
After premedication with analgesic, the wound bed tissue was sharply debrided to remove all nonviable tissue followed by application of the formulated collagen gel. Weekly visits, sharp debridement, and intervention with type I formulated collagen gel continued for a total of 8 weeks. At the 1-and 2-week follow-up visits, additional sharp debridement was performed (after effective premedication) to expose the entirety of the wound bed. The 1-and 2-week follow-up visit measurements increased because of the ability to finally visualize the true wound bed (1 week measurements: 2.3 Â 2.6 Â 2.1 cm [ Figure 3B ]; 2-week measurements: 2.3 Â 2.4 Â 1.7 cm [ Figure 3C ]). By week 6, the wound measured 1.9 Â 1.8 Â 0.6 cm, representing a 71% decrease in wound volume ( Figure 3E) . Concurrently, the wound bed tissue increased in granulation and decreased in nonviable type with each consecutive visit, necessitating less sharp debridement with each visit. At week 7, there was negligible slough and necrotic tissue, and the wound had decreased in volume by 87% (1.8 Â 1.7 Â 0.3 cm; Figure 3F) , and by the final visit at week 8, the ulcer volume had decreased by 93% (1.6 Â 1.6 Â 0.2 cm; Figure 3G ). The type I formulated collagen gel was stopped at that time. In the 4 weeks following the study period, this ulcer continued to improve with decreasing wound volume and maintenance of granulation 
DISCUSSION
In healthy individuals, the wound healing process is usually efficient. However, in cases where wounds are associated with comorbidities (eg, diabetes) or medications that impair healing, there are imbalances in the wound physiology (including excess proteases) that prohibit progression of the wound healing process. 14 Collagen plays an essential and active role in each phase of the normal wound healing cascade by providing a physical scaffold for cellular adhesion, migration, and proliferation, as well as a substrate for growth factor interactions and the needed signaling for sustaining granulation tissue formation and PERCENT VOLUME REDUCTIONS re-epithelialization. 15, 16 The purpose of this study was to evaluate the ability of type I formulated collagen gel, a ready-to-use sterile homogenate of purified fibrillar type I dermal collagen, to promote healing of chronic heel PrUs.
The 3 study patients (2 men and 1 woman) ranged from 75 to 81 years of age. All 3 patients had heel PrUs of at least 12 months' duration. At the start of the study period, the wounds ranged from 5 to 17 cm 2 in area and 4 to 7 cm 3 in volume. Following a weekly regimen of sharp debridement (if clinically needed) and topical application of formulated collagen gel, each patient exhibited increased wound granulation and decreased wound surface area in the 8-week study period. Figure 4 shows the progressive reduction in wound area exhibited in each patient after 4 and 8 weekly applications of formulated collagen gel. Figure 5 shows the corresponding reductions in wound volume.
Weekly application of formulated collagen gel resulted in a progressive and robust increase in wound granulation (decrease in wound volume) in all 3 cases. After only 4 weekly applications of formulated collagen gel, the PrUs decreased volumetrically by 44% to 84%. After 8 weekly applications, the volumes had decreased by 93% to 100%. Establishment of a bed of healthy granulation tissue in turn enabled wound epithelialization, as evidenced by reductions of 49% to 98% in surface areas at week 8.
The patients were monitored for the 4 weeks following the official 8-week study period (without continued application of formulated collagen gel), and all 3 PrUs continued to improve. Patient 1 achieved complete closure with 100% epithelial tissue, and patients 2 and 3 continued to exhibit decreases in wound volume and maintenance of 100% granulation tissue in the wound beds.
SUMMARY
The heel is the second most common location for PrUs, and although less frequent than forefoot ulcers in diabetics, heel ulcers are more costly to treat and less likely to heal. 11, 12 Therefore, new and effective topical treatments for heel PrUs are needed by clinicians in order to successfully pursue ulcer healing and limb salvage. Type I formulated collagen gel offers a novel, effective, and easy-to use intervention for chronic heel PrUs that have not responded to other treatments. All 3 patients in this study re-sponded favorably to weekly treatment with formulated collagen gel, exhibiting robust granulation tissue development. The study was terminated at 8 weeks, yet all 3 PrUs continued to improve in the 4 weeks following the study period (in the absence of further application of formulated collagen gel). Continued application of formulated collagen gel beyond 8 weeks may accelerate such continued improvement, thus avoiding potential complications. Furthermore, randomized clinical trials are necessary to determine the effectiveness of type I formulated collagen gel as compared with conventional topical treatments.
